Previous
Previous

Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.

Next
Next

Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.